Clinical Trials Browser

Phase 2 × Withdrawn × Ovarian Neoplasms × Clear all

NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06120972 2025-02-12

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Phase 2 Withdrawn

Ovarian Neoplasms

NCT05145569 2025-01-01

Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer

Phase 2 Withdrawn

Ovarian Neoplasms

NCT04102436 2024-03-12

Non-Viral TCR Gene Therapy

Phase 2 Withdrawn

BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Urogenital Neoplasms

NCT05201001 2023-09-11

APX005M

Phase 2 Withdrawn

Ovarian Neoplasms

NCT03933761 2021-08-10

PRECISE

Phase 2 Withdrawn

GynecologicSarcoma

Carcinosarcoma, Ovarian Neoplasms

NCT04239014 2021-03-10

DUETTE

Phase 2 Withdrawn

Ovarian Neoplasms

NCT04561817 2020-10-06

To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 2 Withdrawn

Ovarian Neoplasms, Recurrence

NCT00753740 2020-06-12

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Phase 2 Withdrawn

Neoplasms, Ovarian Neoplasms

NCT01766622 2019-12-04

18F-CP18 Imaging Studies for Cancer Treatment With Birinapant

Phase 2 Withdrawn

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02948101 2019-03-12

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00005645 2018-09-18

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

Phase 2 Withdrawn

GynecologicThoracic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pleural Effusion, Malignant

NCT02836028 2018-09-18

A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer

Phase 2 Withdrawn

Ovarian Neoplasms

NCT03032614 2017-10-10

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Phase 2 Withdrawn

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT00408967 2017-08-18

Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.

Phase 2 Withdrawn

Neoplasms, Ovarian Neoplasms, Recurrence

NCT00003865 2017-07-13

Toremifene in Treating Patients With Ovarian Cancer

Phase 2 Withdrawn

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00634894 2016-04-20

Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02017678 2014-09-17

Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin

Phase 2 Withdrawn

Carcinoma, Ovarian Neoplasms, Vaccinia

NCT01131039 2013-12-20

Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00085527 2013-09-05

FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer

Phase 2 Withdrawn

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00006267 2013-07-09

Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2 Withdrawn

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00369954 2013-06-10

Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin

Phase 2 Withdrawn

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01661868 2012-08-21

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00824811 2012-08-02

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel

Phase 2 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Lacrimal Apparatus Diseases, Lung Neoplasms, Endophthalmitis, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Lacerations, Small Cell Lung Carcinoma

NCT00610792 2009-07-14

Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

Phase 2 Withdrawn

Ovarian Neoplasms